AvantiCell delivers leading-edge solutions for customers wishing to evaluate bio-activity or bio-safety in a wide-range of test materials, from pharmaceuticals, traditional medicines and natural products to medical devices and nano-structured materials. AvantiCell solutions use advanced cell culture technology based on physiologically-relevant human and animal cells.

AvantiCell provides its expertise in a range of services ranging from off-the-shelf cell-based assays to specialist cell culture systems customised to meet customers’ requirements. AvantiCell also supplies a growing range of cell products, extending from primary cell isolates to fully validated assay systems. The cell systems can be delivered in the form of pre-assembled models, making cell-based analysis available to customers in easy-use, off-the-freezer-shelf formats.

The Company’s initial focus was on assays for cancer therapeutic discovery. This focus has widened to include assays targeting the molecular events of other major human diseases, and to more general toxicological assays applicable to all drug development.

Assay systems developed by AvantiCell are used to investigate bioactivity in a range of materials from single molecular entities to complex biochemical mixtures such as might be found in natural products or traditional medicines.


Founded 2006:

AvantiCell was set up by a small group of founding investors and is not a spinout company

Private/public shareholder base

AvantiCell private investment is coupled with venture capital investment matched by Scottish Government

Board of Directors

  • Chair: Douglas Thompson
  • Non-executive: Peter Bishop
  • Executive: Colin Wilde PhD

Business Strategy

Ethical Framework

AvantiCell was founded on the principle that cell-based technologies offer valuable preclinical alternatives to animal testing. AvantiCell use of human cells and access to human “surgical excess” tissue adheres to national ethical guidelines and is approved by the West of Scotland Research Ethics Committee.

Organic Growth

AvantiCell is committed to re-investing commercial income in company growth and new technology development. The company is profitable, allowing it to undertake both individual and collaborative research and development projects, all with commercial objectives, to grow our technology base and provide customers with leading-edge cell-based tools and platforms.

Our Founding Principle

AvantiCell's founding principle is that advances in cell culture technology enable the development of physiologically-relevant alternatives to animal testing.